PharmaBlock Sciences Nanjing Inc
SZSE:300725
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Price:
31.85
CNY
1.11%
Market Closed
Market Cap:
6.4B
CNY
Balance Sheet
Balance Sheet Decomposition
PharmaBlock Sciences Nanjing Inc
PharmaBlock Sciences Nanjing Inc
| Current Assets | 2.7B |
| Cash & Short-Term Investments | 596.5m |
| Receivables | 405.9m |
| Other Current Assets | 1.7B |
| Non-Current Assets | 2.2B |
| Long-Term Investments | 5.5m |
| PP&E | 1.7B |
| Intangibles | 462.8m |
| Other Non-Current Assets | 55.5m |
Balance Sheet
PharmaBlock Sciences Nanjing Inc
PharmaBlock Sciences Nanjing Inc
Currency: CNY
Millions
Annual
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
14
|
61
|
78
|
158
|
264
|
145
|
1 245
|
693
|
1 138
|
508
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
693
|
1 138
|
508
|
|
| Cash Equivalents |
14
|
61
|
78
|
158
|
264
|
145
|
1 245
|
0
|
0
|
0
|
|
| Short-Term Investments |
2
|
0
|
0
|
0
|
0
|
22
|
108
|
405
|
467
|
1 090
|
|
| Total Receivables |
13
|
22
|
30
|
40
|
40
|
88
|
171
|
221
|
341
|
478
|
|
| Accounts Receivables |
10
|
20
|
27
|
38
|
35
|
80
|
167
|
201
|
330
|
474
|
|
| Other Receivables |
4
|
2
|
3
|
2
|
5
|
8
|
4
|
20
|
11
|
4
|
|
| Inventory |
31
|
43
|
77
|
117
|
144
|
207
|
310
|
448
|
676
|
725
|
|
| Other Current Assets |
8
|
7
|
6
|
116
|
60
|
76
|
40
|
37
|
37
|
17
|
|
| Total Current Assets |
68
|
133
|
191
|
431
|
509
|
537
|
1 873
|
1 804
|
2 660
|
2 818
|
|
| PP&E Net |
28
|
31
|
75
|
93
|
126
|
258
|
309
|
1 173
|
1 661
|
1 753
|
|
| PP&E Gross |
28
|
31
|
75
|
93
|
126
|
258
|
309
|
1 173
|
1 661
|
1 753
|
|
| Accumulated Depreciation |
14
|
18
|
28
|
39
|
54
|
73
|
96
|
261
|
334
|
437
|
|
| Intangible Assets |
2
|
2
|
10
|
20
|
24
|
25
|
34
|
111
|
111
|
109
|
|
| Goodwill |
0
|
0
|
7
|
7
|
7
|
31
|
31
|
356
|
356
|
356
|
|
| Long-Term Investments |
2
|
2
|
1
|
1
|
81
|
154
|
157
|
9
|
6
|
5
|
|
| Other Long-Term Assets |
1
|
5
|
16
|
16
|
14
|
25
|
21
|
53
|
68
|
62
|
|
| Other Assets |
0
|
0
|
7
|
7
|
7
|
31
|
31
|
356
|
356
|
356
|
|
| Total Assets |
102
N/A
|
173
+70%
|
299
+73%
|
567
+90%
|
761
+34%
|
1 029
+35%
|
2 425
+136%
|
3 507
+45%
|
4 862
+39%
|
5 104
+5%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
3
|
7
|
14
|
19
|
29
|
31
|
56
|
116
|
276
|
193
|
|
| Accrued Liabilities |
5
|
9
|
10
|
17
|
23
|
18
|
33
|
61
|
93
|
110
|
|
| Short-Term Debt |
0
|
0
|
4
|
1
|
25
|
156
|
248
|
531
|
301
|
322
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
15
|
370
|
|
| Other Current Liabilities |
6
|
10
|
12
|
17
|
76
|
74
|
138
|
72
|
54
|
61
|
|
| Total Current Liabilities |
14
|
26
|
40
|
55
|
153
|
278
|
476
|
789
|
739
|
1 056
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
24
|
1 392
|
1 139
|
|
| Deferred Income Tax |
0
|
0
|
2
|
2
|
1
|
1
|
1
|
13
|
20
|
24
|
|
| Minority Interest |
0
|
1
|
9
|
8
|
0
|
0
|
0
|
200
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
3
|
7
|
7
|
9
|
54
|
54
|
53
|
53
|
|
| Total Liabilities |
15
N/A
|
27
+85%
|
54
+101%
|
72
+34%
|
161
+124%
|
288
+79%
|
531
+84%
|
1 079
+103%
|
2 205
+104%
|
2 272
+3%
|
|
| Equity | |||||||||||
| Common Stock |
43
|
50
|
55
|
73
|
110
|
145
|
154
|
200
|
200
|
200
|
|
| Retained Earnings |
41
|
19
|
18
|
85
|
203
|
333
|
496
|
967
|
1 261
|
1 439
|
|
| Additional Paid In Capital |
4
|
115
|
174
|
339
|
288
|
318
|
1 313
|
1 299
|
1 075
|
1 090
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
54
|
65
|
35
|
0
|
20
|
|
| Other Equity |
0
|
0
|
1
|
1
|
2
|
2
|
3
|
3
|
122
|
123
|
|
| Total Equity |
87
N/A
|
146
+67%
|
245
+68%
|
495
+102%
|
600
+21%
|
741
+24%
|
1 895
+156%
|
2 427
+28%
|
2 658
+9%
|
2 832
+7%
|
|
| Total Liabilities & Equity |
102
N/A
|
173
+70%
|
299
+73%
|
567
+90%
|
761
+34%
|
1 029
+35%
|
2 425
+136%
|
3 507
+45%
|
4 862
+39%
|
5 104
+5%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
108
|
127
|
139
|
186
|
186
|
186
|
187
|
198
|
200
|
199
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
